Product level footprinting information (2028) - Market Insight Survey

Introduction

The NHS Net Zero Supplier Roadmap has been developed and implemented collaboratively by the NHS, suppliers and their trade associations to achieve the NHS target of reaching net zero by 2045, as set out in Delivering a Net Zero National Health Service. The 2028 milestone of the Net Zero Supplier Roadmap sets out the intention to introduce new requirements on the provision of carbon footprinting information for targeted products supplied to the NHS from April 2028.

This insights survey forms part of our continued efforts to work in partnership with industry in alignment with Action 21 of the Life Sciences Sector Plan. It is intended for suppliers to the NHS of pharmaceuticals, medical technologies and digital products, which are the three areas initially in scope of the 2028 policy. The survey questions will inform the ongoing development of the 2028 milestone policy and its implementation and should not be interpreted as an indication of future policy.

Please join our introductory webinars on **4th or 8th of December** to find out more information about the purpose of the 2028 milestone and how this survey will support the policy development. Register to attend through our events page.

Please refer to the supporting documents available to download including:

- Standards and methodologies referenced
- Glossary
- Frequently Asked Questions (FAQs) for further information, including data handling questions.
- Offline copy of the survey

All responses, including where only partially completed should be submitted by **12pm 18th January 2027.** The survey should take approximately **30-40** minutes to complete for one product category, dependent on your previous experience with product carbon footprinting.

Publication reference: PRN02403_i

All responses will be analysed by NHS England, who may share your responses internally. Aggregated and anonymised findings will be shared with members of the Carbon Accounting Technical Reference Group on a confidential basis. Key findings may be published, or shared with stakeholders including other healthcare systems, regulators and via our trade body forums and targeted supplier-facing engagement sessions, in aggregated and/or non-attributable form.

If you have any questions not addressed by the supporting materials, please contact england.ccf-sustainability@nhs.net.

Survey questions

About your organisation

The Five Years of a Greener NHS report established that the new requirements on carbon footprinting of products will focus on understanding high carbon emission areas, particularly pharmaceuticals, medical technologies and digital. We are seeking to gather information from suppliers of these products.

(Required*) identifies mandatory questions in this and future sections.

1. Please select the option that best describes your role in responding to these questions. If you supply more than one category (high carbon emission area) please select one category and respond accordingly. To respond for a second category, following submission, please reopen the survey and respond to questions according to the second category. (single select)*
   - Supplier of medicines to the NHS
   - Supplier of medical technology to the NHS
   - Supplier of digital products including hardware, software, AI and data hosting to the NHS
   - Other (move to Engagement section Qu 26)

2. We want to understand how organisation size or type affects survey responses. Please select the option that best describes your organisation. *
   - Large company (250+ employees and annual turnover £50m+)
   - Small or medium sized enterprise (SME) (defined by meeting 2 of the following criteria: 0-249 employees, a turnover under £54 million or a balance sheet total under £27 million)
   - Micro sized company (defined by meeting 2 of the following criteria: under 10 employees, annual turnover under £1m or a balance sheet total under £500k)
   - Voluntary, community or social enterprise (VCSE)

NHS Relationship

3. Which of the following best describes your organisation's role in supplying products to the NHS? (please specify for Other)*
   - Manufacturer – originator
   - Manufacturer – off patent
   - Distributor or reseller

- Both originator and distributor/reseller
- Other

4. Approximately what percentage of your organisation's revenue comes from the NHS in England?
   - less than 5%
   - 5-20%
   - 21-50%
   - 51% or more
   - Don't know

NHS Suppliers on the journey to net zero

The NHS Net Zero Supplier Roadmap sets out steps to help suppliers progress on their net zero journey, in line with the NHS net zero ambition and collaboration within the healthcare supply chain. The intention is to align with emerging international standards, and existing initiatives from other health systems and broader UK government wherever possible and relevant.

5. How important do you think the following are to achieve a Net Zero NHS? *

	Very important	Important	Not important	Not important at all
A shared vision between the NHS and its suppliers on the journey to Net Zero				
A shared understanding of emissions hotspots across the NHS and its suppliers				
Alignment of NHS approaches with international standards and methods				

Category portfolio size

Please respond to all questions from this point onwards for the high carbon emission area (category) you have selected in question 1.

6. Approximately how many individual products or Stock Keeping Units (SKUs) do you supply to health systems in the areas of pharmaceuticals or medical technologies or digital?
   - Less than10
   - 11-100
   - 101-500
   - 501-1,000
   - 1,001-5,000
   - 5,001 - 10,000
   - 10,001 – 20,000
   - 20,001 – 50,000

- More than 50,000
- Don’t know

Current activity

The 2028 milestone of the Net Zero Supplier Roadmap sets out the intention to introduce new requirements on the provision of carbon footprinting information for targeted products supplied to the NHS from April 2028.

The Five Years of a Greener NHS report clarified that multi-impact life cycle assessments (LCAs) would not be required for the 2028 milestone, with the roadmap’s focus on net zero. It is expected that the climate change impact assessment within an LCA is likely to contribute to meeting the upcoming requirement for those products in scope.

7. Is your organisation currently undertaking any work to assess the carbon emissions related to the products you supply? (single select) *
   - Yes we are trying to better understand product emissions (move to next)
   - Not yet. We intend to consider product level emissions when we understand the NHS requirements (move to Qu 11)
   - No, we are not considering product level emissions and have no plan to start doing so (move to Qu 11)
   - I don't know (move to Qu 11)

8. If you are working on assessing product level emissions, how much of your product portfolio have you assessed? (please include any form of assessment, including extrapolation from other product assessments of SKUs or individual products)
   - A majority of our product portfolio (50%+ of SKUs)
   - A moderate proportion of our portfolio (10-50% of SKUs)
   - A small proportion of our portfolio (less than 10% of SKUs)
   - None
   - Don’t know

9. Of your organisation’s total carbon emissions approximately what proportion is associated with the products you have already assessed? (single select)
   - More than 50%
   - 10-50%
   - Less than 10%
   - Don’t know

10. What is your preferred approach to assessing the carbon emissions of your products and why? (free text)

11. Which levels of granularity in a product’s hierarchy do you consider useful for assessing carbon emissions to inform decarbonisation actions? (if selecting other

please specify) (Please rank your top 2 options, where 1 is the most important.)

- Product category – secondary level or lower grouping (where primary = pharmaceuticals, medical technologies, digital)
- Product type - representative
- Individual product or Stock Keeping Unit (SKU)
- Don't know
- Other

12. Which lifecycle stage consistently represents the largest carbon emissions of the products you supply to the NHS? (single select)
    - Material or data acquisition and pre-processing
    - Production
    - Distribution and storage
    - Use stage
    - End of life
    - The spread of carbon emissions across the lifecycle stages of our products are not consistent
    - Don't know

13. Please provide any further detail that would help to clarify your responses in this section and improve our understanding of the insights you have shared. (free text)

Product knowledge

14. Please indicate the proportion of your product portfolio for which you hold each of the following types of information? (select all that apply) (multi select) *
    - Bill of materials held for less than 50% of portfolio
    - Bill of materials held for 50-75% of portfolio
    - Bill of materials held for 75%+ of portfolio
    - Material weights held for less than 50% of portfolio
    - Material weights held for 50-75% of portfolio
    - Material weights held for 75%+ of portfolio
    - Component weights held for less than 50% of portfolio
    - Component weights held for 50-75% of portfolio
    - Component weights held for 75%+ of portfolio
    - We do not hold any bill of materials information
    - A bill of materials is not relevant for my supply sector
    - Don't know

Strategic drivers, value and benefits

We want to develop an approach that provides benefits to both suppliers and the NHS. In particular, improving collective understanding of hotspots will help inform future action, prioritisation, measurement of progress and identify opportunities for collaboration and innovation.

We have confirmed the requirements will focus on three core areas (pharmaceuticals,

medical technologies and digital products). Our intention is to further prioritise by targeting select products within those categories. This policy will therefore not apply to all products in the three areas, but only to targeted sub-categories that will maximise impact.

15. Have you been asked to provide a Product Carbon Footprint (PCF) or similar approach to assess the carbon impact of one of more of the products you supply by any national body, regulator or customer? Please specify the organisation/s where possible in 'other' (multi select) *
    - Yes, by NHS organisations in England
    - Yes, by other health care systems outside of England
    - Yes, by other customers
    - Yes, by a regulator
    - No
    - Other

16. We want to understand how suppliers would prioritise products within their portfolio for carbon assessment. Please indicate which of the below you consider are most beneficial for your prioritisation? (select up to 3)
    - Strategic products – high value
    - Strategic products – high volume
    - Strategic products – critical minerals or components
    - Products in the development stage
    - Products planned for reformulation or redesign
    - Products undergoing regulatory re-approval
    - Products with high estimated carbon footprint
    - Products with low estimated carbon footprint compared to alternatives
    - Products with primary activity data available
    - Products with opportunities for sales growth
    - Other

17. Based on your organisation's experience to date, to what extent has understanding the carbon impact of the products you supply delivered the following benefits?

	Significant benefit	Moderate benefit	Minor or no benefit	Too early to say	N/A
Commercial / competitive advantage with customers	◯	◯	◯	◯	◯
Cost efficiencies	◯	◯	◯	◯	◯
Emissions reduction	◯	◯	◯	◯	◯
Improved processes or	◯	◯	◯	◯	◯

product design						
Increased product circularity	◯	◯	◯	◯	◯	
Material efficiency	◯	◯	◯	◯	◯	
Energy efficiency						
Informing corporate sustainability actions	◯	◯	◯	◯	◯	
Supporting regulatory requirements	◯	◯	◯	◯	◯	
Improved supply chain resilience	◯	◯	◯	◯	◯	
Improving accuracy of scope 3 accounting	◯	◯	◯	◯	◯	
Meeting shareholder/investor expectations	◯	◯	◯	◯	◯	

18. Please provide any further detail that would help to clarify your responses in this section and improve our understanding of the insights you have shared? (free text)

Barriers and Enablers

We want to ensure the requirements are proportionate and continue to set out steps to help suppliers progress on their net zero journey, in line with the NHS net zero ambition.

19. What barriers are there, if any, for your organisation to calculate a PCF for one or more of the products you supply? Do you anticipate barriers in sharing the PCF data with the NHS or publicly? Please clarify how you have identified these barriers e.g. from practical experience, research, knowledge sharing networks or other method. [free text]

20. What sector-specific initiatives would support your organisation to assess the carbon impacts of the products you supply through product carbon footprint calculations or similar? (multi select)

	Very useful	Useful	Not very useful	Not at all useful	Most useful if developed through sector collaboration	N/A

Product carbon footprint calculation tools	○	○	○	○	○	○
Product carbon emission databases	○	○	○	○	○	○
Sector-specific standards or guidance e.g. product category rules	○	○	○	○	○	○
Data sharing platforms	○	○	○	○	○	○
Data sharing arrangements	○	○	○	○	○	○

Deployment

We want to ensure the way the requirements are embedded in the procurement process is proportionate and continues to help suppliers progress on their net zero journey, in line with the NHS net zero ambition.

The requirement will focus on the disclosure of PCF information. The NHS does not intend to use reported carbon footprint figures to rank products within procurement processes with the 2028 policy. This policy is primarily about improving collective understanding to deliver the expected benefits.

It is likely the requirements will be gradually phased in from April 2028, focusing on priority products with maximum opportunity for impact and key procurement opportunities such as new frameworks or framework renewals.

21. How should product carbon footprint information be requested through the procurement process to optimise decarbonisation across the healthcare supply chain. Please indicate if you think the approach could also support supplier recognition and reward. (free text) *

Core questions summary

22. Please provide any additional information you think would be helpful to improve our understanding and interpretation of your insights shared. (Free text)

PCF experience to share

The Five Years of a Greener NHS report clarified that multi-impact life cycle

assessments (LCAs) would not be required for the 2028 milestone, with the roadmap's focus on net zero. It is expected that the climate change impact assessment within contribute to an LCA is likely to meeting the upcoming requirement for those products in scope.

23. We would like to gain further insights from suppliers who have experience undertaking product carbon footprinting, including where carbon was calculated as part of a wider Life Cycle Assessment (LCA). If you have relevant experience, would you be willing to share this by completing an additional set of relevant questions? (single select)*.
    - Yes, I will share our experience (branch to next).
    - I am not able to share our experience (move to category specific questions)
    - We do not have experience to share (move to category specific questions)

Product carbon footprint (PCF) Current activity

Throughout this survey PCF is used as a generic term to refer to activity to assess the carbon footprint of a product, irrespective of the method used. If you have performed an assessment of broader environmental impacts (such as Life Cycle Assessment), please provide your experience, only considering the climate change impact assessment in your response.

24. Approximately, what proportion of your product portfolio (by number of individual products/SKUs) has a product carbon footprint (PCF)? (single select)
    - Less than 1%
    - 1-5%
    - 6-10%
    - 11-25%
    - More than 25%

Product Footprint experience

In this section, please share one of your most recent experiences of completing a Product Carbon Footprint (PCF). Responses to questions 27 to 41 should be relevant to the product named in question 26. If you have any additional examples of PCF experience, you will be given the opportunity to share additional experience at the end of this section.

25. For the experience you are sharing, please provide the product name (for an individual product or SKU), and its categorisation (e-class or British National Formulary category or Government Commercial Agency digital categorisation as appropriate) (free text) *

26. What type of assessment was undertaken?*
    - Product Carbon Footprint
    - Life Cycle Assessment

27. When did you undertake the assessment? *
    - Less than 3 years ago
    - More than 3 years ago

28. Do you, have previous experience of undertaking a PCF? If you repeated an assessment, please explain why at 'other' (multi select)
    - It was our first assessment
    - It was an update to an existing assessment
    - We have used the methodology previously for another product
    - Other

29. What is the cost for the individual product? (select one option in (£ GBP)
    - £0-1
    - £2-10
    - £11-100
    - £101-1000
    - £1001 – 10,000
    - £10,000 +

30. What proportion of your total sales does this product represent (total sales revenue to the NHS in England)? (select one)
    - Less than 1%
    - 1-5%
    - 6-10%
    - 11-25%
    - More than25%

31. What standard or methodology did you apply, if any? Please use 'Other' to specify and provide a URL for the methodology where possible for any response option that is not a named standard or methodology. (multi select) *
    - Cloud Carbon Footprint
    - Customer developed standard or approach
    - EU Product Environmental Footprint (PEF) EF 3.1
    - French Government's carbon footprint of medicines assessment methodology
    - GHG Protocol Product Life Cycle Accounting and Reporting Standard
    - Greenhouse Gas Accounting Sector Guidance for Pharmaceutical Products and Medical Devices (ERM and NHS Sustainable Development Unit), 2012
    - Green Software Foundation – Software Carbon Intensity (SCI)
    - ISO 14040 and 14044
    - ISO 14067
    - ITU-TL.1410
    - ITU -T L.1801
    - PACT framework
    - PAS 2050:2011
    - PAS 2090:2025
    - Own methodology
    - Sector specific product category rules
    - Together For Sustainability, The Product Carbon Footprint Guideline for the

Chemical Industry, 2024
- Don’t know
- Other

32. What was the cost of producing the PCF for the individual product or single SKU excluding any assurance/verification costs (Please only include monetised costs, non-monetised internal staff time is covered in a later question)? (select one, in £ GBP) *
    - £0 internal resources only
    - Less than £500
    - £501 - £1,000
    - £1,001 - £5,000
    - £5,001 - £10,000
    - £10,001 - £30,000
    - £30,001 - £50,000
    - £50,001 - £100,000
    - More than £100,000

33. How long did it take for the PCF to be completed, from the time the exercise was started to obtaining a final result? *
    - <1 month
    - 1-3 months
    - 4 - 6 months
    - > 6 months

34. Who undertook the PCF exercise for your organisation? (single select)
    - Internal resources only
    - Mixed (internal and external resources)
    - External organisations / 3rd party

35. What was the approximate total time (in full-time equivalent person months) your internal resources spent on the PCF exercise?
    - <1 month
    - 1-3 months
    - 4 - 6 months
    - > 6 months

36. If you externally assured/verified your PCF, please provide the approximate cost of undertaking assurance/verification.
    - <£1,000
    - £1,001 - £5,000
    - £5,001 - £10,000
    - £10,001 - £30,000
    - £30,001 - £50,000
    - >£50,000
    - Did not assure or verify

37. How does your organisation share or plan to share any product-level emissions

information collected? Please select the most relevant response and specify where possible at 'other' for example the statutory requirement. (multi select)

- Internal use only e.g. product development
- Formal internal reporting e.g. Board reports, KPIs
- Share confidentially with customers
- Share with trusted partner organisations or collaborative groups
- Publish results externally
- Publish results externally to meet requirements (e.g. statutory requirements announced),
- Publish results externally where data is independently verified e.g. Environmental Product Declarations
- Don't know
- Other (free text)

38. What benefits, if any, resulted from completing the PCF? Please include how the PCF improved your understanding of emissions, the main emission hotspots you found and how this supported your decarbonisation actions for the specific product and more broadly. (free text)

39. Please provide any further information that would help to clarify the responses provided in this section on PCF experience (free text)

40. If you published your PCF results, could you please share the link? If your results were not published and you are able to share them, please email them to england.ccf-sustainability@nhs.net, outlining any confidentiality requirements. [optional / Free text]

Additional Experience to share

41. If you have completed more than one PCF, please list the additional products you have assessed, indicating why they were selected, what you have learned from replicating the process, including any benefits and actions taken as a result. (free text)

42. Can you provide any further detailed examples of PCF experience? If you select yes, you will be able to answer questions on PCF experience questions for another product)*

- Yes (branching to repeat)
- No (move to next)

Note – the number gap in numbering between question s42 and 76 represents the duplication of PCF experience questions, allowing survey responders to submit examples of up to 3 products.

Future plans

76. In the next 3 years, what proportion of your product portfolio (by number of individual products/SKUs) do you intend to have a PCF for?

- <1%
- 1-5%
- 6-10%
- 11-25%
- >25%
- Don’t know

77. What are your plans over the next 3 years, if any, for undertaking further PCF calculations across your product portfolio? Please include what product groups / lines this applies to and your rationale for selecting them? [Free text]

Category specific branching question

78. Please select the product categories you supply to the NHS. You will be moved to category specific questions and given the opportunity to complete the questions for another category if you supply, or intend to supply to the NHS more than one category listed below (single select): *
    - Medical technologies, equipment and consumables only (move to Medtech Qu 27)
    - Medicines manufacturing, transport and or distribution only (move to Medicines Qu 31)
    - Digital products (hardware/software/cloud hosting/AI) only (move to Digital Qu 36)
    - Medical technologies as well as medicines or digital products (move to Medtech Qu 27 first)

Medical Technology specific questions

79. From the PCF methodology you have tested for the experience shared (as noted at question 10), what is your preferred method for undertaking a PCF for your medical technology product / product group. Please explain its advantages and disadvantages? [Free text]

80. What barriers, if any, do you anticipate in gathering input (primary) data to produce a PCF? (free text)

81. Could you please explain the source/s of your secondary data, including carbon emission factors [Free text]

82. Do you supply or intend to supply to the NHS any medicines (manufacturing, transport and or distribution) or digital products? (you will then be moved to category specific questions if relevant) *
    - Yes - medicines related products (move to next)
    - Yes - medicines and digital related products (move to next)
    - Yes - digital related products (move to Digital Qu 36)
    - No (move to experience section Qu 54)

Medicines specific questions

83. From the PCF methodology you have tested for the experience shared (as noted at question 10), what is your preferred method for undertaking a PCF for your medicines product / product group. Please explain its advantages and disadvantages? [Free text]

84. What barriers, if any, do you anticipate in gathering input (primary) data to produce a PCF? (free text)

85. Could you please explain the source of your secondary data, including carbon emission factors [Free text]

86. Do you supply or intend to supply Digital related products to the NHS (this includes hardware, software, data hosting and AI products)? (you will be moved to digital specific questions if relevant) *
    - Yes (move to Digital Qu 36)
    - No (move to survey end Qu 54)

Digital specific questions

87. From the PCF methodology you have tested for the experience shared (as noted at question 10), what is your preferred method for undertaking a PCF for digital products / product groups. Please explain its advantages and disadvantages? [Free text]

88. What barriers, if any, do you anticipate to gathering input (primary) data to produce a PCF? (free text)

89. Could you please explain the source of your secondary data, including carbon emission factors [Free text]

90. Do you use or plan to use any other standard or initiatives as part of understanding the carbon emissions of your products? If so, which one(s) and why? (free text)

DIGITAL - HARDWARE

91. Do you supply digital hardware products to the NHS? (you will be moved to the

next section if you answer no) *

- Yes (move to next)
- No (move to Qu 43)

92. Which types of digital hardware do you supply to the NHS? (multi select)
    - End-user devices
    - Hardware bundled with services
    - Networking equipment
    - Servers or storage equipment
    - Specialist or clinical digital hardware
    - Other

93. At which level could you provide carbon information for your hardware? (multi select)
    - Hardware delivered as part of a service
    - Individual product model or configuration
    - Product group or category
    - Representative product models
    - Not currently available
    - Don’t know
    - Other

DIGITAL - SOFTWARE

94. Do you supply Software products to the NHS? (you will be moved to the next section if you answer no) *
    - Yes (move to next)
    - No (move to Qu 47)

95. How is your software primarily delivered? (multi select)
    - Bundled with services
    - Hybrid or managed
    - On premise
    - Software-as-a-Service (SaaS)
    - Other

96. Which functional unit do you currently use to calculate the PCF for your software? (multi select)
    - Per organisation or deployment
    - Per transaction or request
    - Per user
    - Per workload or runtime
    - Service-level aggregate only
    - Don’t know
    - Other (please specify)

97. What factors drive emissions of your software? (Please select at most 3 options)

- Compute intensity
- Data storage
- Data transfer
- End-user devices
- Hosting environment
- Software design efficiency
- Don’t know
- Other

DIGITAL - DATA HOSTING (including Cloud)

98. Do you supply data hosting (including cloud) products to the NHS? (you will be moved to the next section if you answer no) *
    - Yes (move to next)
    - No (move to AI Qu 50)

99. Which functional unit do you currently use to calculate the product carbon footprint of hosting or cloud services? (multi select)
    - Per customer environment
    - Per unit of compute
    - Per unit of storage
    - Per unit of data transfer
    - Per workload or application
    - Service-level aggregate
    - Don’t know
    - Other (please specify)

100. What factors drive emissions from hosting or cloud services? (Please select at most 3 options.)
    - Energy source
    - Geographic location of services
    - Infrastructure efficiency
    - Utilisation rates
    - Virtualisation or multi-tenancy
    - Don’t know
    - Other

DIGITAL - AI ENABLED DIGITAL SERVICES

101. Do you supply an AI product to the NHS? (you will be moved to the next section if you answer no) *
    - Yes (move to next)
    - No (move to survey end Qu 54)

102. Which AI-related activities are relevant to your services? (multi select) -
    - Advanced analytics and decision support

- Continuous learning or retraining
- Model inference and data processing
- Model training
- Pre-trained model integration
- Staff or patient-facing interaction
- Agentic AI
- Other

103. Which functional unit do you currently use to calculate the product carbon footprint for AI enabled services? (multi select)
    - Aggregate service-level only
    - Per training run
    - Per inference or request
    - Per model version
    - Per service or deployment
    - Not currently feasible
    - Other (please specify)

104. Which AI lifecycle stages drive emissions for your services? (Please select at most 3 options.)
    - Advanced analytics and decision support
    - Continuous learning or retraining
    - Data preparation and storage
    - Infrastructure provisioning
    - Model inference and data processing
    - Model training
    - Staff or patient-facing interaction
    - Don’t know
    - Other

Summary

105. Is there any further information you wish to share (free text)? (move to engagement section)

Engagement

106. We value supply chain engagement opportunities to inform our work, including improving our understanding of the costs, benefits and resource implications for different approaches to product carbon footprinting. Would you like to engage further with our work? (multi select) *
    - I would like to be invited to future webinars on the 2028 milestone
    - I would be open to a follow up discussion on my response
    - I would like to be added to a distribution list for email updates on the programme
    - No (move to end of form)

Please provide your email address:_____

Please provide your name, job title and organisation:_____

Data Handling

NHS England acknowledges that some information provided may be commercially sensitive. Identifying specific information where you consider this to be the case will help NHS England to take this into account if a request for related information is received.

107. Please identify the relevant information considered commercially sensitive and explain why disclosure would prejudice your commercial interests or otherwise cause harm? (free text)

Survey End – closing notes

Thank you for completing this survey and helping us to gather insights on product-level carbon foot printing. NHS England may use the information provided through this survey to inform the development of future policy, guidance and roadmap activities.

We will be in touch if you have provided contact details and indicated you would like to participate in further engagement activity.

By responding to this survey, you acknowledge that information submitted may be subject to statutory rights of access and that NHS England may be required to disclose information where the relevant legal tests for withholding it are not met. Please see the FAQs for further information on data handling.

Regarding our use of personal data, please see our private notice: https://www.england.nhs.uk/contact-us/privacy-notice/.

You can contact us on england.ccf-sustainability@nhs.net or england.sustainablemedicines@nhs.net.

Thank you,
Net Zero and Sustainable Procurement Team, Greener NHS team, Medicines Net Zero Team, Digital Net Zero Team